Danaher to launch AI-powered autonomous research lab in 2027
1 source↑ Market-relevant
IN SHORT
Life sciences firm Danaher announced plans to launch its first AI-powered autonomous research lab, designed to accelerate drug discovery and development. The lab, expected to operate at scale in early 2027, will integrate AI, robotics, and technologies from various Danaher companies to create custom antibodies and molecular tools.
life sciences company launching AI-powered autonomous research lab
JC Gutierrez-Ramos
chief science officer of Danaher, stating scientists can focus on complex challenges
Julie Sawyer Montgomery
President and Chief Executive Officer of Danaher, stating the lab reflects Danaher's progress
↳ Why This Matters
The development signifies a significant step in applying AI and automation to accelerate drug discovery and the creation of molecular tools, potentially leading to faster breakthroughs in life sciences research and development.
Key facts
Danaher plans to launch its first AI-powered autonomous research lab.
The lab is expected to operate at scale in early 2027.
It will combine AI, robotics, and technologies from several Danaher operating companies.
The lab aims to make discovering molecules eight times faster.
It is projected to unlock a tenfold increase in generating target-binding molecules annually.
The lab uses AI to create new molecules, builds and tests them, and feeds results back into the model.
Life sciences company Danaher announced plans to launch its first AI-powered autonomous research lab, designed to accelerate drug discovery and development. The lab, expected to operate at scale in early 2027, will integrate artificial intelligence, robotics, and technologies from various Danaher operating companies into a connected workflow.
The initiative aims to make the discovery of custom antibodies and other molecular tools up to eight times faster and increase annual reagent generation by tenfold. According to JC Gutierrez-Ramos, chief science officer of Danaher, this will free up scientists to focus on more complex challenges requiring human insight.
The lab operates on a continuous design-make-test-learn loop, where AI helps create new molecules, which are then built, tested, and their results fed back into the model to improve subsequent designs. This process is based at Abcam, a Danaher company, and incorporates technologies from other Danaher entities including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, with automation support from Automata.
Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher, stated that the autonomous lab reflects the company's ability to accelerate the journey from discovery to impact by applying its science, technology, and culture of continuous improvement. This lab is the first step in a broader Danaher program to create a fleet of smart instruments, integrated workflows, and autonomous labs to speed up scientific research.
Frequently asked questions
It is a laboratory that uses artificial intelligence and robotics to automate and accelerate scientific processes, such as drug discovery, by integrating design, testing, and learning loops.
Technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices are being integrated, with Abcam serving as the base for the lab.
The lab is projected to make discovery up to eight times faster and increase annual reagent generation by tenfold, allowing scientists to focus on complex challenges.
What Happens Next
01The lab is expected to operate at scale in early 2027.
✉Newsletter
Pick the topics you care about. Get only what matters, on your cadence.
How It Developed
Danaher announced plans to launch its first AI-powered autonomous research lab.
